Roles for Innate Immunity in Combination Immunotherapies
Open Access
- 1 October 2017
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 77 (19), 5215-5221
- https://doi.org/10.1158/0008-5472.can-17-1340
Abstract
Immunity to infectious agents involves a coordinated response of innate and adaptive immune cells working in concert, with many feed-forward and regulatory interactions between both arms of the immune system. In contrast, many therapeutic strategies to augment immunity against tumors have focused predominantly on stimulation of adaptive immunity. However, a growing appreciation of the potential contributions of innate immune effectors to antitumor immunity, especially in the context of combination immunotherapy, is leading to novel strategies to elicit a more integrated immune response against cancer. Here we review antitumor activities of innate immune cells, mechanisms of their synergy with adaptive immune responses against tumors, and discuss recent studies highlighting the potential of combination therapies recruiting both innate and adaptive immune effectors to eradicate established tumors. Cancer Res; 77(19); 5215–21. ©2017 AACR.Keywords
This publication has 52 references indexed in Scilit:
- Exploiting a natural conformational switch to engineer an interleukin-2 ‘superkine’Nature, 2012
- Targeting natural killer cells and natural killer T cells in cancerNature Reviews Immunology, 2012
- Cancer immunotherapy via dendritic cellsNature Reviews Cancer, 2012
- Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancerJCI Insight, 2012
- The role of interleukin-2 during homeostasis and activation of the immune systemNature Reviews Immunology, 2012
- Safety and Efficacy of Combination Immunotherapy With Interferon Alfa-2b and Tremelimumab in Patients With Stage IV MelanomaJournal of Clinical Oncology, 2012
- Adoptive Transfer of Autologous Natural Killer Cells Leads to High Levels of Circulating Natural Killer Cells but Does Not Mediate Tumor RegressionClinical Cancer Research, 2011
- Allogeneic natural killer cells for refractory lymphomaCancer Immunology, Immunotherapy, 2010
- Monoclonal antibodies: versatile platforms for cancer immunotherapyNature Reviews Immunology, 2010
- Involvement of neutrophils and natural killer cells in the anti-tumor activity of alemtuzumab in xenograft tumor modelsLeukemia & Lymphoma, 2010